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Abstract
Background: Previously, a total of five breast cancer subtypes have been identified based on
variation in gene expression patterns. These expression profiles were also shown to be associated
with different prognostic value. In this study tumour samples from 27 breast cancer patients,
previously subtyped by expression analysis using DNA microarrays, and four controls from normal
breast tissue were included. A new MetriGenix 4D™ array proposed for diagnostic use was
evaluated.
Methods: We applied MetriGenix custom 4D™ arrays for the detection of previously defined
molecular subtypes of breast cancer. MetriGenix 4D™ arrays have special features including probe
immobilization in microchannels with chemiluminescence detection that enable shorter
hybridization time.
Results: The MetriGenix 4D™ array platform was evaluated with respect to both the accuracy in
classifying the samples as well as the performance of the system itself. In a cross validation analysis
using "Nearest Shrunken Centroid classifier" and the PAM software, 77% of the samples were
classified correctly according to earlier classification results.
Conclusion: The system shows potential for fast screening; however, improvements are needed.
Background
A feature common to all commercialized or in-house
DNA expression arrays up to date is the two-dimensional
nature of the format. An array platform (MetriGenix 4D™
Array System, MetriGenix, Toronto, Ontario, Canada) was
introduced in which molecular interactions occur within
three-dimensional volumes of ordered microchannels
rather than at a two-dimensional surface [1]. The micro-
channel geometry partition target solution into small vol-
umes that enhance the mass transport of targets to probes,
resulting in reduced hybridization times and provides
greater binding capacity. The method described here uti-
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lizes the proprietary Universal Linkage system (ULS®)
technology from Kreatech Biotechnology (Amsterdam,
The Netherlands) for linking biotin to amplified RNA
[2,3]. The probes are detected by single-colour chemilu-
minescence with high sensitivity [4]. MetriGenix devel-
oped a special designed hybridization station and
detection unit to process custom 4D arrays.
Molecular signatures based on gene expression patterns of
breast carcinomas, specifying different subtypes of
tumours, have been identified by the use of DNA microar-
rays [5-7]. Specifically, the set of 552 "intrinsic" genes
reported by Perou and Sorlie [6] was found to segregate
breast cancers into 5 distinct groups based on gene expres-
sion profile. This profile has been validated in later studies
and also shown to have prognostic value [5,7-9]. Two of
the subtypes (luminal A and luminal B) belong to the
estrogen receptor positive (ER+) group of tumours, while
the tumours in the three other subgroups (basal-like,
ERBB2+ and normal-like) in general, all are estrogen
receptor negative (ER-). Interestingly, the estrogen recep-
tor alpha and HER2/ERBB2, the major parameters charac-
terizing 3 of the 5 different classes, are the goals for the
most successful targeted therapies in breast cancer, under-
lining a fundamental role in biological control.
Gene expression patterns from 269 genes selected to opti-
mally define the different subtypes of breast cancer were
analyzed in breast tumours and normal tissue from 31
individuals (20 early breast carcinomas, 7 locally
advanced breast carcinomas and 4 normal tissue sam-
ples). The aim of this pilot study was to investigate
whether this type of arrays would have the potential as a
diagnostic tool for molecular classification in a clinical
setting.
Here we show that the MetriGenix 4D™ arrays with a lim-
ited number of carefully selected probes, perform simi-
larly to other microarray platforms, although technical
difficulties were experienced with the prototype system.
Methods
Tumour material and RNA extraction
In total, 27 breast tumour samples and 4 normal tissue
samples were analyzed in this study. Among the tumour
samples, 20 biopsy tissues from early breast carcinomas
were included of which ten have been previously sub-clas-
sified as luminal subtypes, the other half as non-luminal
subtypes using traditional two-dimensional microarray
platforms such as Stanford cDNA arrays, Agilent Human
Whole Genome Arrays and Applied Biosystems Human
Genome Survey Microarrays [10]. Furthermore, tumour
tissues from 7 locally advanced breast cancers were also
included. These samples are part of a cohort of thirty-five
patients, and have previously been described [11]. Three
were classified as luminal subtypes and four as non-lumi-
nal subtypes [9]. In addition, control samples were taken
from mastectomy specimens from four breast cancer
patients. We selected tissue distant from the tumour, and
verified that it consisted of unaffected breast tissue by HE
(haematoxylin-eosin) stains of frozen sections. The scien-
tific protocols (tissue sampling and laboratory analysis) of
the samples were approved by the Regional Committee
for Medical Ethics (health region II) for the M-samples
(reference S- 97103) and Regional Committee for Medical
Ethics (health region III) for the F-samples (reference 39/
92–69.91).
Total RNA was extracted from fresh frozen tissue samples
by using TRIzol®  (Invitrogen, Carlsbad, CA, USA) as
described by the manufacturer. The RNA quality was eval-
uated by microcapillary electrophoresis using an Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA,
USA) and concentration measured by using NanoDrop
(NanoDrop Technologies, Wilmington, DE, USA).
Selection of genes immobilized on the MetriGenix-Chip
We selected 269 genes that best represented the classifica-
tion scheme in breast cancer to be synthesized and immo-
bilized on the MetriGenix-Chip (see Additional file 1 for
a complete listing of probes). The genes were selected
from the intrinsic gene list as defined in Perou et al. 2000
[6] and Sorlie et al. 2001/2003 [8,9] by a semi-supervised
method. A nearest shrunken centroid analysis using PAM
was performed to reduce the number of genes in the clas-
sification scheme. Thus, the top 226 genes from this list
were included in the 269 selected for syntheses. In addi-
tion, genes that distinguish lobular from ductal carcino-
mas [12], and cell cycle associated genes were added to the
chip to enable other types of classification.
MetriGenix-Chip-Preparation and hybridization
Total RNA was amplified using a two-step cRNA synthesis
scheme typical for microarray experiments. First strand
cDNA was synthesized by annealing T7-(T) 24- primer
(100 pmol/μl) with 5 μg total RNA in a final volume of 12
μl at 70°C for 10 min, followed by addition of first-strand
master mix (5× First Strand Buffer, 0.1 M DTT, 10 mM/
each dNTPs mix, 25 U/μl RNaseOUT and 200 U/μl Super-
Script II) to a final volume of 20 μl. The reaction was incu-
bated at 42°C for one hour. Second strand synthesis
followed immediately by adding 5× Second Strand Buffer,
10 mM/each dNTPs mix, 10 U/μl E.coli DNA Ligase, 10 U/
μl E.coli DNA Polymerase I and 2 U/μl RNaseH to a final
volume of 150 μl, and incubating at 16°C for two hours.
To complete the reaction, 5 U/μl T4 DNA Polymerase
were added and further incubated at 16°C for five min (all
reagents supplied by Invitrogen). Double-stranded cDNA
was purified in Phase-Lock Gel Tubes (Eppendorf AG,
Hamburg, Germany) and in vitro transcribed by Ambion'sBMC Cancer 2006, 6:59 http://www.biomedcentral.com/1471-2407/6/59
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MEGAscript ™ T7 High Yield Transcription kit (Ambion,
Inc. Austin, TX, USA) followed by cleanup with RNeasy®
RNA isolation kit columns (Qiagen). Amplified cRNA was
evaluated on the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies). The cRNA was biotin-labelled using MetriGe-
nix Bio ULS (universal linkage system) (0.5 Units/μl) in a
one-step chemical coupling reaction at 85°C for 30 min
(MetriGenix and KreaTech Biotechnology, Amsterdam,
The Netherlands).
Prior to hybridization the biotin-labelled cRNA were
mixed with spike-in controls (for hybridization quality),
Sample Dilution Buffer 2 (MetriGenix) and herring sperm
DNA (Invitrogen) and denatured for 5 min at 90°C. The
sample was then injected into the sample compartment of
the 4D array, along with blocking and staining reagents
into their respective compartments.
Custom 4D arrays to monitor the genes of interest were
supplied by MetriGenix (Baltimore, Maryland). For each
gene, a 50- to 60-mer probe was designed based on pub-
licly available sequences and to have GC content in the
range of 45 to 55 percent and a melting temperature
between 64 and 68°C. For product quality control (QC)
the following steps were performed: First, hybridization
was performed with just the complements to the control
probes to confirm that there was no cross-contamination
of probes on the chip. Second, a test cRNA was hybridized
to the chip in the absence of the control targets; since the
controls were bacterial and the test cRNA mammalian, no
hybridization was observed in the control probes (other-
wise the chips failed QC). Third, control targets were
added to every cRNA that was hybridized to the chip and
the intensity of the spots was used qualitatively to confirm
the hybridization results. Probes were synthesized with a
5' amino modification and printed on MetriGenix arrays
using a Gene Machine Omnigrid arrayer. The arrays are
housed in a 4D cartridge that includes reagent reservoirs
and interfaces with the MGX2000 and MGX1200CL array
processing stations.
4D array hybridizations were performed on the MGX™
2000 hybridization station, which controlled all subse-
quent steps (blocking and buffer flushes, hybridization
time and temperature). After four hours of hybridization
(3 h for hybridization to the corresponding probes and 1
h for blocking, washing and staining of the reactive spots
with HRP-streptavidin), the chip was placed in the MGX
1200 CL detection unit for chemiluminescence (CL)
detection with exposure times usually ranging from 2 to 5
s. Subsequent image analysis was performed with the
MetriSoft software (MetriGenix) that generated an excel
file containing the experiment data for subsequent analy-
sis.
Data analysis
The Metrisoft software operated on two different con-
cepts, the noise floor and a stringent threshold value, to
filter spots in the individual chip analysis. The noise floor
was a value calculated by the software in each individual
chip analysis that related to the amount of noise in the
chip and which was subsequently used to determine the
threshold value. The stringent threshold value was calcu-
lated as 3 times the noise floor, an empirical estimate of
an 'absent' spot based on the image noise. Any signal
below this value was not considered significant and
assigned to the threshold value. For intra-chip normaliza-
tion, the signal intensity of each individual spot was
divided by the threshold to produce the normalized val-
ues within each chip. Data from 3 successful hybridized
controls (one control with poor chip image was rejected
from further analysis) were averaged for each gene to
obtain a mean expression value. Next, to create log-trans-
formed (base 2) pseudo ratios the value of each sample
was divided by the mean of the three controls for every
gene.
Principal Component Analysis (PCA), hierarchical clus-
tering and ANOVA were performed by using Avadis Pro-
phetic software (Strand Genomics, Bangalore, INDIA).
Data were mean-centered, clustered using Euclidean dis-
tance measures and visualized using a heat map in which
numeric values are represented in colour intensities (high
levels in red, low levels in green). For ANOVA, samples
were assigned class designations and gene expression data
were analyzed assuming equal variance. Data were ranked
based on p-values and F-statistics. In addition, a set of
genes that best discriminated the two identified main sub-
types of breast cancer were determined using "Nearest
Shrunken Centroid classifier" and the PAM software [13].
For this analysis, pseudo ratios were generated using an
average of all tumour samples as the denominator, to pre-
vent the normal tissue samples from driving the analysis.
PAM analysis was also performed with the pseudo ratios
used for PCA, ANOVA and clustering analysis (see above)
with similar results (data not shown).
Results and discussion
The aim of this study was to demonstrate whether these
novel arrays would have the potential to be used in molec-
ular classification in a diagnostic setting in a future imple-
mentation. The limited number of MetriGenix chips
available in this study allowed us to successfully hybridize
and analyze altogether 25 of 31 samples (16 early breast
carcinoma-, 6 locally advanced breast carcinoma- and 3 of
the controls). Therefore, in the further evaluation with
respect to the accuracy in classifying the samples we con-
centrated on the luminal (luminal A and B) vs. non-lumi-
nal (basal-like, ERBB2+ and normal-like) groups instead
of all five subtypes.BMC Cancer 2006, 6:59 http://www.biomedcentral.com/1471-2407/6/59
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Statistical analysis of luminal versus non-luminal tumours
To evaluate the data generated by the MetriGenix analy-
ses, an ANOVA analysis was performed excluding the con-
trol samples to identify the genes that best separated the
samples into two groups; luminal and non-luminal (see
Additional file 2). Genes with a p < 0.01 (n = 43) were
used in a hierarchical clustering and a clear separation of
the luminal and non-luminal samples was seen (figure 1).
The tumours previously classified as luminal A showed
moderate to high expression of luminal epithelial specific
genes including the ESR1, GATA3, XBP1, MUC1 while the
basal-like tumours showed no expression of these genes.
Further, the luminal cluster was divided into four sub-
groups corresponding to the luminal A (dark blue), lumi-
nal B (light blue), the latter with less expression of lumi-
nal epithelial specific genes expressed, the previously
identified ERBB2+ - (purple) and the normal-like group
(green). Although there were few samples analyzed in this
study, those representing each subtype grouped together.
To test whether the clustering pattern could be visualized
by using data from all the 226 "intrinsic" only genes
printed on the 4D array, a hierarchical clustering was per-
formed (see Additional file 3). As previously noted, the
basal-like tumours formed a distant group, whereas the
remaining tumours clustered together on a separate
branch.
To further evaluate the dataset, prediction of tumour sub-
types was performed using the PAM software and the
results are shown in figure 2. Using a threshold of 1.2, 27
genes were selected that were differential expressed
between the two sample groups; luminal and non-lumi-
nal (see Additional file 4). Of these, 13 were also found
significant (p < 0.01) in the ANOVA analysis (see Addi-
tional file 2). Ten-fold cross-validated probabilities were
computed for luminal (group 1, blue diamonds) and
non-luminal (group 2, pink squares) tumours. Samples
M88 and M91 (both luminal B) were not classified since
the CV probabilities was about 0.5. Furthermore, the
luminal B sample F5 and the two ERBB2+ samples M53
and F35 were misclassified by the ten-fold cross-valida-
tion. One explanation may be that the luminal B expres-
Hierarchical clustering of luminal and non-luminal breast  tumour samples Figure 1
Hierarchical clustering of luminal and non-luminal 
breast tumour samples. The 43 most significant genes 
from the ANOVA analysis (luminal vs. non-luminal, p < 0.01), 
excluding the control samples, were used in a hierarchical 
clustering analysis. Coloured branches represent the differ-
ent subtypes as previously determined using other DNA 
microarray platforms [9,10]: Dark blue = luminal A, light blue 
= luminal B, green = normal-like, red = basal-like and purple 
= ERBB2+. M = early breast cancer, F = locally advanced 
breast cancer.
Prediction of tumour subtypes using PAM Figure 2
Prediction of tumour subtypes using PAM. Cross-vali-
dated probabilities are shown for luminal tumours (group 1, 
blue diamonds) and non-luminal tumours (group 2, pink 
squares). Coloured samples names represent the different 
subtypes previously determined using different microarray 
technologies: Dark blue = luminal A, light blue = luminal B, 
green = normal-like, red = basal-like and purple = ERBB2+. M 
= early breast cancer, F = locally advanced breast cancer.BMC Cancer 2006, 6:59 http://www.biomedcentral.com/1471-2407/6/59
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sion profile have some common features both with the
luminal A and with the basal-like expression profiles as
seen in previous studies [6,8,9].
Principal component analysis (PCA), based on all genes
on the 4D array, confirmed the groupings of samples seen
in the hierarchical clustering analysis (figure 3). Again, a
major distinction of the basal-like samples was observed.
Microarray platform performance
The sample preparation procedure including two-step
cRNA synthesis and hybridization/detection was accom-
plished in three days. An advantage of the system was the
short hybridization time of four hours; however, the mul-
tiple-day sample preparation protocol makes the overall
analysis not much shorter than other microarray plat-
forms. The system throughput was limited to a single chip
per hybridization unit and the handling and purification
was difficult due to small exterior buffer reservoirs and
small buffer tubes, leading to contamination concerns.
Moreover, it was difficult to trace errors, both on the hard-
ware system and the Metrisoft software, as the system
lacked an error message function. For more extensive
applications, the image analysis software will require sig-
nificant refinement. For example, artefacts such as pins-
pots and high background on the sample images occurred
that led to the rejection of several arrays from further anal-
ysis. In addition, when analysing the images in the
Metrisoft software, we consistently observed that the spot-
finder did not find all of the spots on the image and man-
ually re-reading of the image was necessary.
Conclusion
We conclude that by selecting only the data from the well
performed arrays (25/31) and by using key signature
genes for breast-cancer subtypes immobilized on the
MetriGenix 4D™ array, we were able to classify samples
into the same subtypes as they were previously classified
by using other microarray techniques, with a relatively
high probability (23% misclassification). With higher
throughput and improved performance this microarray
platform has the potential to be a valuable tool for rapid
routine gene expression profiling.
Competing interests
DB and AS are previous employees of MetriGenix. Metri-
Genix is a private company that manufactured the arrays
employed in this study, which was performed on a collab-
orative basis. All other authors declare that they have no
competing interests.
Authors' contributions
AM was involved in laboratory experiments, analyzing the
data and drafted the manuscript. HJ was involved in labo-
ratory experiments. DB carried out the statistical compu-
tation of the data. AS were involved in data analysis. PEL
and BN were involved in providing breast cancer samples.
TS and ALBD initiated and designed the study and were
involved in writing the manuscript.
Additional material
Additional File 1
Genes-on-chip. A listing of the genes immobilized on the 4D array along 
with sequence information of each probe.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-59-S1.pdf]
Additional File 2
ANOVA-analysis output. ANOVA analysis of all the genes immobilized 
on the MetriGenix breast cancer chip.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-59-S2.pdf]
Additional File 3
Hierarchical clustering of "intrinsic" only genes. Hierarchical cluster-
ing diagram of the 226 "intrinsic" only gene subset immobilized on the 
MetriGenix chip. Coloured branches represent the different subtypes as 
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Principal Component Analysis (PCA) Figure 3
Principal Component Analysis (PCA). Red squares indi-
cate basal-like samples, green squares indicate all other sam-
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